Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906

References

• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J Y, Harousseau J L, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Martelli M, Vignetti M, Zinzani P L, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli M F, Calabresi F, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534–542
   PubMed Web of Science ®Google Scholar
• Pizzolato J F, Saltz L B. The camptothecins. Lancet 2003; 361: 2235–2242
   PubMed Web of Science ®Google Scholar
• Ulukan H, Swaan P W. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002; 62: 2039–2057
   PubMed Web of Science ®Google Scholar
• Kaufmann S H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991; 51: 1129–1136
   PubMed Web of Science ®Google Scholar
• Eder J P, Chan V, Wong J, Wong Y W, Ara G, Northey D, Rizvi N, Teicher B A. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 1998; 42: 327–335
   PubMed Web of Science ®Google Scholar
• Whitacre C M, Zborowska E, Gordon N H, Mackay W, Berger N A. Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997; 57: 1425–1428
   PubMed Web of Science ®Google Scholar
• Kraut E H, Balcerzak S P, Young D, Davis M P, Jacobs S A. A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study. Cancer Invest 2002; 20: 174–179
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen H A, Kirchen H, Jahnke K, Korfel A. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004; 62: 1885–1887
   PubMed Web of Science ®Google Scholar
• Seiden M V, Ng S W, Supko J G, Ryan D P, Clark J W, Lynch T, Huang K C, Kwiatkowski D, Skarin A, Eder J P, Jr. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res 2002; 8: 691–697
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, Lister T A, Vose J, Grillo-Lopez A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 47: 583–621
   Google Scholar
• Rasheed Z A, Rubin E H. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22: 7296–7304
   PubMed Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol 2001; 2: 733–740
   PubMed Web of Science ®Google Scholar
• Kerbel R S, Kamen B A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423–436
   PubMed Web of Science ®Google Scholar
• Traina T A, Sabbatini P, Aghajanian C, Dupont J. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 2004; 95: 235–241
   PubMed Web of Science ®Google Scholar
• Coutinho F, Manhani A R, Velasquez W S, Del Giglio A. Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial. Acta Haematol 2004; 112: 121–125
   PubMed Web of Science ®Google Scholar
• Younes A, Preti H A, Hagemeister F B, McLaughlin P, Romaguera J E, Rodriguez M A, Samuels B I, Palmer J L, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001; 12: 923–927
   PubMed Web of Science ®Google Scholar
• Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang N H, Samaniego F, Rodriguez M A, Fayad L. Taxol plus topotecan plus rituximab (TTR) with G-CSF support: an effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who failed CHOP-like and platinum-based therapy. Blood 2003; 102a
   Google Scholar
• Kancherla R R, Nair J S, Ahmed T, Durrani H, Seiter K, Mannancheril A, Tse-Dinh Y C. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase – DNA complex formation with clinical response. Cancer 2001; 91: 463–471
   PubMed Web of Science ®Google Scholar
• Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma 2002; 43: 1581–1587
   PubMed Web of Science ®Google Scholar